Chronic kidney disease (CKD) is a serious condition that affects millions of people worldwide. In its most advanced stage, known as stage 5 CKD or end-stage renal disease (ESRD), the kidneys are no longer able to function properly and require dialysis or a kidney transplant to sustain life. Patients with stage 5 CKD are at a significantly higher risk of cardiovascular events, such as heart attacks and strokes, as well as kidney-related complications.
Recent research published in Renal and Urology News has shown that the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with stage 5 CKD can help reduce the risks of both cardiovascular and kidney events. SGLT2 inhibitors are a class of medications commonly used to treat type 2 diabetes by lowering blood sugar levels through the excretion of glucose in the urine.
The study, which included over 4,000 patients with stage 5 CKD, found that those who were prescribed SGLT2 inhibitors had a significantly lower risk of cardiovascular events, such as heart attacks and strokes, compared to those who were not taking the medication. Additionally, patients who were treated with SGLT2 inhibitors had a reduced risk of kidney-related complications, such as the need for dialysis or kidney transplant.
These findings are significant because patients with stage 5 CKD are at a high risk of developing cardiovascular and kidney-related complications, which can significantly impact their quality of life and overall health. By using SGLT2 inhibitors, healthcare providers can help reduce these risks and improve outcomes for patients with stage 5 CKD.
It is important to note that while SGLT2 inhibitors have shown promising results in reducing the risks of cardiovascular and kidney events in patients with stage 5 CKD, further research is needed to fully understand the long-term effects of these medications in this population. Healthcare providers should carefully consider the risks and benefits of prescribing SGLT2 inhibitors to patients with stage 5 CKD and tailor treatment plans to individual patient needs.
In conclusion, the use of SGLT2 inhibitors in patients with stage 5 CKD has been shown to reduce the risks of cardiovascular and kidney events, according to recent research published in Renal and Urology News. Healthcare providers should consider incorporating these medications into treatment plans for patients with stage 5 CKD to help improve outcomes and reduce complications associated with this serious condition.
- The Renal Warrior Project. Join Now
- Source: Plato Data Intelligence.
- Source: https://renal.platohealth.ai/sglt2-inhibitor-use-in-stage-5-ckd-cuts-risks-for-cardiovascular-kidney-events-renal-and-urology-news/